Pancreatic Cancer Research

ResearcherVa North Texas Health Care SystemActive in the last 2 years

Ravikanth Maddipati

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0317-1361; OpenAlex author ID A5036659748; NIH RePORTER profile ID 10936064. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
2
Labs led
1
Collaborators
58
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: none · 2024: none · 2025: 1 paper, 1 grant · 2026: 1 paper, 1 grant

Papers 9

  1. Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.drup.2025.101312↗
  2. Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention. Co-author DOI 10.1172/jci191943↗
  3. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2022.04.011↗
  4. Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes. Co-author DOI 10.1016/j.ijrobp.2022.07.019↗
  5. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-20-1826↗
  6. APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Co-author DOI 10.1038/s43018-021-00268-8↗
  7. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Co-author DOI 10.1016/j.devcel.2018.05.025↗
  8. Pancreatic cancer survival analysis defines a signature that predicts outcome. First author DOI 10.1371/journal.pone.0201751↗
  9. Pancreatic Cancer Metastases Harbor Evidence of Polyclonality. Co-author DOI 10.1158/2159-8290.cd-15-0120↗

Grants 2

  1. Optogenetic engineering of tumor topography in native tissue environments DP2CA290967↗
  2. Role of MIF-CD74 signaling as an immune regulator and therapy target in pancreas cancer. I01BX006978↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rolf A. Brekken · 2 shared papers, 2022 · strength 0.24
  2. Susan Elaine Bates · 1 shared paper, 2026 · strength 0.23
  3. Maryam Safari · 1 shared paper, 2026 · strength 0.23
  4. Agnès Basseville · 1 shared paper, 2026 · strength 0.23
  5. Kenneth P. Olive · 1 shared paper, 2026 · strength 0.23
  6. Tito Fojo · 1 shared paper, 2026 · strength 0.23
  7. Pichai Raman · 2 shared papers, 2018–2022 · strength 0.22
  8. Ben Z. Stanger · 2 shared papers, 2015–2022 · strength 0.21
  9. Faiyaz Notta · 2 shared papers, 2021–2022 · strength 0.20
  10. Jason Robert Pitarresi · 2 shared papers, 2018–2022 · strength 0.16
  11. Andrew D. Rhim · 2 shared papers, 2018–2021 · strength 0.15
  12. Gilbert Zvikomborero Murimwa · 1 shared paper, 2022 · strength 0.14
  13. Sören Müller · 1 shared paper, 2022 · strength 0.14
  14. Huocong Huang · 1 shared paper, 2022 · strength 0.14
  15. Nina Niu Sanford · 1 shared paper, 2022 · strength 0.13
  16. Matteo Ligorio · 1 shared paper, 2022 · strength 0.13
  17. Patricio Marcelo Polanco · 1 shared paper, 2022 · strength 0.13
  18. Ahmed M. Elamir · 1 shared paper, 2022 · strength 0.13
  19. Syed Mohammad Ali Kazmi · 1 shared paper, 2022 · strength 0.13
  20. Todd Anthony Aguilera · 1 shared paper, 2022 · strength 0.13
  21. Muhammad Shaalan Beg · 1 shared paper, 2022 · strength 0.13
  22. Matthew R. Porembka · 1 shared paper, 2022 · strength 0.13
  23. Herbert J. Zeh · 1 shared paper, 2022 · strength 0.13
  24. Aydın Tözeren · 1 shared paper, 2018 · strength 0.12
  25. Kian‐Huat Lim · 1 shared paper, 2018 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.